Chondroitin Sulfate Proteoglycan 4 (CSPG4) as a Potential Biomarker for Fetal Growth Restriction: Insights from an Umbilical Cord Blood Analysis.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-09-01 DOI:10.7754/Clin.Lab.2024.240436

Zeynep Seyhanli, Burak Bayraktar, Gulsan Karabay, Betul T Cakir, Mevlut Bucak, Gizem Aktemur, Can O Ulusoy, Serap Sucu, Seray Ozturk, Gulcan K Hekimoglu, Sevki Celen

{"title":"Chondroitin Sulfate Proteoglycan 4 (CSPG4) as a Potential Biomarker for Fetal Growth Restriction: Insights from an Umbilical Cord Blood Analysis.","authors":"Zeynep Seyhanli, Burak Bayraktar, Gulsan Karabay, Betul T Cakir, Mevlut Bucak, Gizem Aktemur, Can O Ulusoy, Serap Sucu, Seray Ozturk, Gulcan K Hekimoglu, Sevki Celen","doi":"10.7754/Clin.Lab.2024.240436","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to evaluate the umbilical cord blood chondroitin sulfate proteoglycan 4 (CSPG4) concentrations in pregnancies complicated with fetal growth restriction (FGR) and aimed to investigate the rela-tionship between the CSPG4 levels in these pregnancies and adverse neonatal outcomes.Methods: This prospective case-control study was conducted between August 2023 and January 2024. The study included 80 singleton pregnancies at 35 to 39 weeks of gestation. Among these, 40 were diagnosed with FGR and 40 served as the control group. After the delivery, samples of the cord blood were collected prior to the placental delivery.Results: The CSPG4 levels were significantly higher in the study group (FGR), 1,153 (1,059 - 1,261) pg/mL, than in the control group, 1,107 (873 - 1,197) pg/mL (p = 0.024). When all patients were evaluated, the CSPG4 levels showed a positive correlation with the systolic/diastolic (S/D) ratio of the umbilical arteries (r = 0.276, p = 0.013). A statistically significant negative correlation was observed between the levels of CSPG4 in the umbilical cord blood and the Apgar scores at the 1st (r = -0.256, p = 0.022) and 5th (r = -0.250, p = 0.026) minutes. The discriminatory power of the umbilical cord CSPG4 level in the determination of composite adverse neonatal outcomes was evaluated by ROC analysis and a cutoff point of > 1,091.25 pg/mL, showing a sensitivity of 93.3%, a specificity of 46.2%, and an AUC of 0.661 (95% CI: 0.547 - 0.763, p = 0.019).Conclusions: Elevated levels of CSPG4 have been observed in the umbilical cord blood in pregnancies complicated by FGR; higher levels are associated with adverse neonatal outcomes.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 9","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240436","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to evaluate the umbilical cord blood chondroitin sulfate proteoglycan 4 (CSPG4) concentrations in pregnancies complicated with fetal growth restriction (FGR) and aimed to investigate the rela-tionship between the CSPG4 levels in these pregnancies and adverse neonatal outcomes.

Methods: This prospective case-control study was conducted between August 2023 and January 2024. The study included 80 singleton pregnancies at 35 to 39 weeks of gestation. Among these, 40 were diagnosed with FGR and 40 served as the control group. After the delivery, samples of the cord blood were collected prior to the placental delivery.

Results: The CSPG4 levels were significantly higher in the study group (FGR), 1,153 (1,059 - 1,261) pg/mL, than in the control group, 1,107 (873 - 1,197) pg/mL (p = 0.024). When all patients were evaluated, the CSPG4 levels showed a positive correlation with the systolic/diastolic (S/D) ratio of the umbilical arteries (r = 0.276, p = 0.013). A statistically significant negative correlation was observed between the levels of CSPG4 in the umbilical cord blood and the Apgar scores at the 1st (r = -0.256, p = 0.022) and 5th (r = -0.250, p = 0.026) minutes. The discriminatory power of the umbilical cord CSPG4 level in the determination of composite adverse neonatal outcomes was evaluated by ROC analysis and a cutoff point of > 1,091.25 pg/mL, showing a sensitivity of 93.3%, a specificity of 46.2%, and an AUC of 0.661 (95% CI: 0.547 - 0.763, p = 0.019).

Conclusions: Elevated levels of CSPG4 have been observed in the umbilical cord blood in pregnancies complicated by FGR; higher levels are associated with adverse neonatal outcomes.

查看原文本刊更多论文

硫酸软骨素蛋白多糖 4 (CSPG4) 作为胎儿生长受限的潜在生物标记物：脐带血分析的启示。

研究背景本研究旨在评估合并胎儿生长受限（FGR）的孕妇脐带血中硫酸软骨素蛋白多糖4（CSPG4）的浓度，并探讨这些孕妇的CSPG4水平与新生儿不良结局之间的关系：这项前瞻性病例对照研究于 2023 年 8 月至 2024 年 1 月间进行。研究包括 80 例妊娠 35 至 39 周的单胎妊娠。其中 40 例被诊断为 FGR，40 例为对照组。分娩后，在胎盘娩出前采集脐带血样本：研究组（FGR）的 CSPG4 水平为 1,153 (1,059 - 1,261) pg/mL，明显高于对照组的 1,107 (873 - 1,197) pg/mL（P = 0.024）。在对所有患者进行评估时，CSPG4 水平与脐动脉收缩/舒张（S/D）比值呈正相关（r = 0.276，p = 0.013）。脐带血中的 CSPG4 水平与第 1 分钟（r = -0.256，p = 0.022）和第 5 分钟（r = -0.250，p = 0.026）的 Apgar 评分之间存在统计学意义上的负相关。通过 ROC 分析评估了脐带 CSPG4 水平对新生儿综合不良结局的判别能力，以 > 1,091.25 pg/mL 为临界点，结果显示灵敏度为 93.3%，特异性为 46.2%，AUC 为 0.661（95% CI：0.547 - 0.763，p = 0.019）：结论：在妊娠合并FGR的孕妇脐带血中观察到CSPG4水平升高；较高的水平与新生儿的不良预后有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.